Vaccines, a company owned by Pharmsintez, will begin to develop and create production of dry nutrient media for the Sputnik V vaccine and the HFB30132A monoclonal antibody against coronavirus. The company will borrow ₽2 billion from the Russian Technological Development Fund to finance the project. It is planned to be implemented by 2024.